Skip to content
sellNotable cluster of 5

Matthew Maxwell Donley sold $994k of AUPH

Chief Operating Officer at Aurinia Pharmaceuticals Inc.. 124,893 shares at an average of $7.96, traded Mar 3, 2025, filed Mar 4, 2025.

Warning score
65
Value
$994k
124,893 shares
Holdings after
680,465
-16% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    COO
    +20
  • Trade size
    $994k at market
    +25
  • Share of holdings sold
    Sold 16% of holdings
    +5
  • Cluster
    5 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -0.4%, 3m -1.0%, 6m +44.6%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AUPHOct 9, 2026 · close 16.65
Since filing Mar 4, 2025: +106.1%SPY +37.5% · excess +68.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001600620-25-000018, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 28, 2025AGrant or award
Common Stock
+82,781$0.00$0669,791Mar 4, 2025
Mar 3, 2025AGrant or award
Common Stock
+135,567$0.00$0805,358Mar 4, 2025
Mar 3, 2025SOpen-market sale
Common Stock
-65,902$8.00$527k739,456Mar 4, 2025
Mar 4, 2025SOpen-market sale
Common Stock
-58,991$7.92$467k680,465Mar 4, 2025
Feb 28, 2025AGrant or award
Employee Stock Option (right to buy)derivative
+126,416$0.00$0126,416Mar 4, 2025

Related signals

Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
27Weak
AUPHsell
Aurinia Pharmaceuticals Inc.
Stephen P. Robertson
Chief Legal Officer
$190k
11,939 shares
-2%
30Weak
AUPHsell
Aurinia Pharmaceuticals Inc.
Stephen P. Robertson
Chief Legal Officer
$356k
20,975 shares
-3%
53Moderate
AUPHbuy
Aurinia Pharmaceuticals Inc.
Kevin C Tang
Chief Executive Officer
$12M
814,606 shares
+7%
43Moderate
AUPHbuy
Aurinia Pharmaceuticals Inc.
Kevin C Tang
Chief Executive Officer
$13M
900,000 shares
+8%
43Moderate
AUPHbuy
Aurinia Pharmaceuticals Inc.
Kevin C Tang
Chief Executive Officer
$14M
1,300,000 shares
+13%
32Weak
AUPHsell
Aurinia Pharmaceuticals Inc.
Greg Keenan
Chief Medical Officer
$210k
20,000 shares
-13%
38Weak
AUPHsell 5
Aurinia Pharmaceuticals Inc.
Greg Keenan
Chief Medical Officer
$68k
8,305 shares
-5%
48Moderate
AUPHbuy
Aurinia Pharmaceuticals Inc.
Kevin C Tang
Chief Executive Officer
$13M
1,600,000 shares
+19%
60Notable
AUPHsell 5
Aurinia Pharmaceuticals Inc.
Stephen P. Robertson
EVP, General Counsel
$975k
122,479 shares
-19%
66Notable
AUPHsell 5
Aurinia Pharmaceuticals Inc.
Joseph M Miller
Chief Financial Officer
$940k
118,013 shares
-17%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Matthew Maxwell Donley sold $994k of AUPH | InsiderTell